Dynavax Technologies Corporation (DVAX) Receives $28.00 Average Price Target from Brokerages

Dynavax Technologies Corporation (NASDAQ:DVAX) has earned a consensus recommendation of “Buy” from the eight analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $28.00.

Several equities analysts have weighed in on the company. William Blair restated an “outperform” rating and set a $30.00 price target on shares of Dynavax Technologies in a report on Wednesday, August 9th. Cowen reiterated an “outperform” rating and issued a $30.00 target price on shares of Dynavax Technologies in a report on Thursday, August 10th. Royal Bank Of Canada reiterated a “buy” rating and issued a $26.00 target price on shares of Dynavax Technologies in a report on Friday, September 1st. ValuEngine upgraded Dynavax Technologies from a “sell” rating to a “hold” rating in a report on Thursday, September 7th. Finally, Cantor Fitzgerald assumed coverage on Dynavax Technologies in a report on Friday, September 15th. They issued an “overweight” rating and a $24.00 target price for the company.

Shares of Dynavax Technologies (DVAX) traded down $0.10 on Friday, reaching $17.30. The company had a trading volume of 1,138,314 shares, compared to its average volume of 1,871,025. Dynavax Technologies has a 52 week low of $3.70 and a 52 week high of $24.45.

Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.15. The company had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.28 million. Dynavax Technologies had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. The firm’s quarterly revenue was down 68.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.90) EPS. equities analysts forecast that Dynavax Technologies will post -1.72 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. GMT Capital Corp raised its position in Dynavax Technologies by 1.7% during the 3rd quarter. GMT Capital Corp now owns 3,057,437 shares of the biopharmaceutical company’s stock valued at $65,735,000 after purchasing an additional 52,300 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Dynavax Technologies by 10.9% in the 2nd quarter. Vanguard Group Inc. now owns 2,024,666 shares of the biopharmaceutical company’s stock worth $19,538,000 after acquiring an additional 199,004 shares in the last quarter. PointState Capital LP bought a new position in shares of Dynavax Technologies in the 2nd quarter worth $13,510,000. State Street Corp raised its position in shares of Dynavax Technologies by 19.7% in the 2nd quarter. State Street Corp now owns 839,218 shares of the biopharmaceutical company’s stock worth $8,099,000 after acquiring an additional 138,112 shares in the last quarter. Finally, C WorldWide Group Holding A S raised its position in shares of Dynavax Technologies by 23.3% in the 3rd quarter. C WorldWide Group Holding A S now owns 823,825 shares of the biopharmaceutical company’s stock worth $17,712,000 after acquiring an additional 155,610 shares in the last quarter. 70.61% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This story was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/3078261/dynavax-technologies-corporation-dvax-receives-28-00-average-price-target-from-brokerages.html.

About Dynavax Technologies

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Analyst Recommendations for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.